MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Bruker Corporation Net Debt 2011-2026 | BRKR
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Bruker Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.91 B | 695 M | 568 M | 262 M | 163 M | 135 M | 18.7 M | 205 M | 69.3 M | -400 K | 35.5 M | -83.7 M | 26.6 M | 57.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.91 B | -83.7 M | 290 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 13.08 | 2.19 % | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.61 | -2.58 % | $ 38 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.22 | - | $ 121 M |  France |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.21 | -4.84 % | $ 317 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 93.7 | -1.24 % | $ 12.7 B | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 26.0 | -1.48 % | $ 220 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.12 | -1.85 % | $ 1.29 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 5.48 | 2.81 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.82 | -2.29 % | $ 371 M | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 10.84 | - | $ 388 M | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 63.41 | -1.23 % | $ 3.46 B |  Britain |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.08 | 1.89 % | $ 18.3 M | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.21 | 2.36 % | $ 62.3 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.87 | -1.23 % | $ 1.18 B | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 55.07 | -2.2 % | $ 1.62 B | USA |
 |
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.28 | 0.79 % | $ 52.1 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 85.35 | -0.78 % | $ 2.96 B | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 83.46 | -0.94 % | $ 48.8 B | USA |
 |
MiMedx Group
MDXG
|
-148 M | $ 3.34 | -2.62 % | $ 494 M | USA |
 |
NanoVibronix
NAOV
|
-4.11 M | - | - | $ 1.08 M | USA |
 |
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.83 | 0.8 % | $ 34.7 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Natus Medical Incorporated
NTUS
|
-64.1 M | - | 1.94 % | $ 1.05 B | USA |
 |
Orthofix Medical
OFIX
|
78.5 M | $ 12.32 | -0.24 % | $ 488 M |  Curacao |